In this Q&A on bioprinting in 3Dprint.com, CRA Life Sciences consultants Pascale Diesel, Lev Gerlovin, and Andrew Thomson discuss the potential applications for 3D bioprinting in the life sciences industry, including the long term impact, commercialization, and regulation of this groundbreaking technology. Key attributes of this emerging technology are its scalability and flexibility, which allows for the manufacturing of a large variety of tissues in an automated and repeatable way. These high-throughput biofabrication capabilities equip developers with exciting tools to develop 3D-tissues for broad applications, from in vitro drug testing models, to therapeutic tissue implants, to whole organ transplants. The bioprinting field is gaining traction at the commercial and technological level, but developmental hurdles are limiting funds flowing to bioprinting players who are attempting to evolve basic-demonstrative technologies through higher levels of proof and technical readiness.
To read more about some of the hurdles facing the 3D bioprinting field, click here.
CRA acquires bioStrategies Group, Inc.
Today CRA announced its acquisition of bioStrategies Group, Inc., a Chicago-based consulting firm focused on developing commercial strategies for healthcare...